Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes.
Key Investor Takeaways – Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue of approximately $99.3 million, driven by continued growth in Amtagvi sales. – The company is reviewing its previously issued 2026 revenue guidance of $350 million to $370 million following stronger-than-expected demand trends. – Gross margin improved to 56%, reflecting higher sales volumes, manufacturing efficiencies and ongoing cost optimisation. – Iovance continues expanding its commercial footprint, with more than 95 authorised treatment centres and at least 110 expected by year-end. – Multiple registrational and next-generation clinical programmes continue to progress, supporting the company’s longer-term growth strategy
Why (NASDAQ:IOVA) Stock Is in Focus Iovance Biotherapeutics (NASDAQ:IOVA) delivered record second-quarter revenue of approximately $99.3 million, a 66% increase from the prior-year quarter and a 39% improvement over the first quarter of 2026, supported by continued demand for its cell therapy, Amtagvi. U.S. Amtagvi revenue reached approximately $91 million during the quarter, while Proleukin contributed about $9 million.
The strong commercial performance prompted management to review its previously issued full-year revenue guidance of $350 million to $370 million, with an updated outlook expected during the third quarter. Gross margin improved to 56% as manufacturing efficiencies and cost optimisation continued to benefit operations, while research and development expenses declined sequentially for a fourth consecutive quarter. Beyond commercial execution, the company continued expanding its treatment network to more than 95 authorised centres across the U.S., Canada and Australia and expects at least 110 active centres by the end of 2026.